NCT05318443 A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer Status COMPLETED Phase PHASE3
NCT05312671 Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer Status RECRUITING Phase PHASE2
NCT05309629 Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma Status RECRUITING Phase PHASE3
NCT05298592 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Status COMPLETED Phase PHASE1
NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05286619 A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) Status RECRUITING Phase PHASE2
NCT05281406 Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) Status RECRUITING Phase PHASE2
NCT05276973 Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05267470 A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) Status TERMINATED Phase PHASE1
NCT05261399 Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05258279 Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations Status COMPLETED Phase PHASE2
NCT05256225 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma Status RECRUITING Phase PHASE3
NCT05247684 AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05244213 Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05241873 (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Status TERMINATED Phase PHASE1
NCT05240898 A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1